Y-Intercept (HK)’s Ocular Therapeutix OCUL Stock Holding History

Y-Intercept (HK)’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$138K	Sell	14,007 -40,696	-74%	-$369K	﹤0.01%	1593
2026 Q1	$463K	Sell	54,703 -340,632	-86%	-$3.25M	0.01%	1277
2025 Q4	$4.8M	Buy	+395,335	New	+$4.8M	0.11%	241
2025 Q3	–	Sell	-36,815	Closed	-$342K	–	1901
2025 Q2	$342K	Buy	+36,815	New	+$288K	0.01%	1324
2024 Q2	–	Sell	-20,523	Closed	-$187K	–	1769
2024 Q1	$187K	Buy	+20,523	New	+$146K	0.01%	1174

Other funds holding OCUL

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

RZH

Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Y-Intercept (HK)'s OCUL Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Ocular Therapeutix (OCUL) stake by 74% in Q2 2026, selling an estimated $369K and leaving 14,007 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Y-Intercept (HK) first reported a position in OCUL in Q1 2024 and has held it in 5 quarters since. The position peaked at $4.8M in Q4 2025. 22 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Y-Intercept (HK) held 14,007 shares of Ocular Therapeutix worth $138K as of Q2 2026.
Y-Intercept (HK) sold 40,696 Ocular Therapeutix shares in Q2 2026, an estimated $369K.
Ocular Therapeutix made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1593 holding.
Y-Intercept (HK) first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 5 quarters since.
Y-Intercept (HK)'s Ocular Therapeutix position peaked at $4.8M in Q4 2025.
22 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.